PCR London Valves 2025: Late-Breaking Trials and Hotlines
Where new data meets clinical impact
At PCR London Valves 2025, the Late-Breaking Trials reveal first-time presentations and major updates from the most relevant studies in structural heart disease. Selected from this year’s Call for Late-Breaking Trials, these sessions showcase primary outcomes and follow-up results from landmark trials and registries - discussed with expert investigators and the audience.
What makes these sessions stand out? They go beyond results - analysing data, questioning outcomes, and opening real dialogue that shapes clinical decisions.
✨ Focus on 8 high-impact presentations
Presented in the Main Arena on Sunday, the Top Late-Breaking Trials feature eight studies, during 2 sessions, with the potential to significantly influence current practice.
A dedicated meet-the-trialists session on Monday, will give the participants the chance to exchange directly with leading investigators.
- The Pivotal Study of DragonFly System: 2 Years Outcomes in China & 6 Months Outcomes in Europe - Maisano Francesco
- AltaValve Early Feasibility Study: One-Year Outcomes with Atrial Fixation TMVR - Vlasis NINIOS
- Safety and Performance of Cardiovalve replacement system for TR: TARGET Study interim results - Georg Nickenig
- One-year results from the ADALA trial - Xavier Freixa
- First in man use of the Vivasure PerQseal® Elite for large hole arterial closure - Nicolas Van Mieghem
- TAVI for aortic regurgitation in high surgical risk: Outcomes in 700 patients from ALIGN-AR - Raj Makkar
- Hypoattenuating leaflet thickening in two balloon expandable TAVI valves - Christian Juhl Terkelsen
- Five-year outcomes following early experience with transapical TMVR - Michael Reardon
Explore more Hotlines
Alongside the Top Late-breaking Trials, four additional Hotline sessions will unveil key findings on TAVI, mitral and tricuspid interventions, and other structural interventions.
Each will deliver valuable insights from ongoing studies and registries, broadening your perspective on the rapidly evolving field of valve therapy.